FEV1 · children and young adults with CF
The review found no eligible studies for this question.
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · children and young adults with CF
1 finding from 1 review
FVC (% predicted) Change from baseline · children and young adults with CF
1 finding from 1 review
Lung function: FEF25‐75 mL/s (percentage change from baseline) · children and young adults with CF
1 finding from 1 review
Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young adults with CF
1 finding from 1 review
HRQoL ‐ all domains (change from baseline) Scale: age‐appropriate versions of the CFQ‐R questionnaire · adults, children and young people with CF
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · adults, children and young people with CF
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · adults, children and young people with CF
1 finding from 1 review
HRQoL ‐ all domains (change from baseline) Scale: age‐appropriate versions of the CFQ‐R questionnaire · adults, children and young people with CF
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · adults, children and young people with CF
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · adults, children and young people with CF
1 finding from 1 review
FVC · adults, children and young people with CF
1 finding from 1 review
Lung function: FEF25‐75 mL/s (change from baseline) · adults, children and young people with CF
1 finding from 1 review
Adverse events relating to treatment Scale: mild, moderate, severe and total · adults, children and young people with CF
1 finding from 1 review
Annual Exacerbation Rates · people with bronchiectasis
Inhaled mannitol showed no clear difference in exacerbations Exacerbation rate per year. compared with placebo (moderate certainty).
1 finding from 1 review
Hospitalisations Number of participants experiencing one of more hospitalisations. · people with bronchiectasis
Inhaled mannitol showed no clear difference in hospitalisations Number of participants experiencing one of more… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · people with bronchiectasis
Inhaled mannitol showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · people with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · people with bronchiectasis
Inhaled mannitol showed no clear difference in health‐related quality of life measured on the SGRQ Scale from 0 to… compared with placebo (moderate certainty).
1 finding from 1 review
Symptoms Bronchiectasis Symptoms Questionnaire · people with bronchiectasis
Inhaled mannitol showed no clear difference in symptoms Bronchiectasis Symptoms Questionnaire compared with placebo (moderate certainty).
1 finding from 1 review